IRIS
ROSSI, GIOVANNI
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 2.132
AS - Asia 17
NA - Nord America 1
SA - Sud America 1
Totale 2.151
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 2.132
CN - Cina 13
SG - Singapore 4
BR - Brasile 1
US - Stati Uniti d'America 1
Totale 2.151
Salva come PNG Salva come JPEG
Città #
Genoa 1.011
Genova 572
Rapallo 304
Vado Ligure 237
Bordighera 8
Beijing 5
Ashburn 1
São Paulo 1
Xi'an 1
Totale 2.140
Salva come PNG Salva come JPEG
Nome #
Baseline serum levels of osteopontin predict clinical response to treatment with nivolumab in patients with non-small cell lung cancer 151
New insights on the role of luteinizing hormone releasing hormone agonists in premenopausal early breast cancer patients 136
Diagnosis of lung cancer following emergency admission: Examining care pathways, clinical outcomes, and advanced NSCLC treatment in an Italian cancer Center 118
Serum PCSK9 levels at the second nivolumab cycle predict overall survival in elderly patients with NSCLC: a pilot study 113
A Circulating Risk Score, Based on Combined Expression of Exo-miR-130a-3p and Fibrinopeptide A, as Predictive Biomarker of Relapse in Resectable Non-Small Cell Lung Cancer Patients 112
Comparison between 18F-FDG-PET- and CT-based criteria in non-small cell lung cancer (NSCLC) patients treated with Nivolumab 110
Releasing the brake: safety profile of immune check-point inhibitors in non-small cell lung cancer 108
New systemic strategies for overcoming resistance to targeted therapies in non-small cell lung cancer 107
Radiomic detection of EGFR mutations in NSCLC 99
The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients 98
CIMAvax-EGF, a therapeutic non-small cell lung cancer vaccine 92
Afatinib and Erlotinib in the treatment of squamous-cell lung cancer 87
Investigational drugs targeting fibroblast growth factor receptor in the treatment of non-small cell lung cancer 86
Vinflunine for the treatment of non-small cell lung cancer 85
Exploring Response to Immunotherapy in Non-Small Cell Lung Cancer Using Delta-Radiomics 83
Front-line liquid biopsy for early molecular assessment and treatment of hospitalized lung cancer patients 81
Microtubule-targeting agents in the treatment of non-small cell lung cancer: insights on new combination strategies and investigational compounds 80
Platelets and their derived extracellular vesicles: The new generation of markers in non-small cell lung cancer management 77
Liquid biopsy in non-small cell lung cancer: Highlights and challenges 76
The evolving role of pemetrexed disodium for the treatment of non-small cell lung cancer 76
Metabolic parameters as biomarkers of response to immunotherapy and prognosis in non-small cell lung cancer (Nsclc): A real world experience 75
Radiomic-based diagnostics in oncology: challenges toward clinical practice 75
The role of the immune metabolic prognostic index in patients with non-small cell lung cancer (Nsclc) in radiological progression during treatment with nivolumab 72
Prognostic relevance of circulating tumor cells and circulating cell-free DNA association in metastatic non-small cell lung cancer treated with nivolumab 33
Totale 2.230
Salva come PNG Salva come JPEG
Categoria #
all - tutte 10.329
article - articoli 10.329
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 20.658
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021235 0 0 0 87 47 3 6 25 26 28 5 8
2021/2022213 19 8 6 10 13 18 1 39 23 26 17 33
2022/2023337 20 23 5 34 76 55 4 24 47 10 38 1
2023/2024223 3 16 3 27 20 40 29 23 12 17 7 26
2024/2025704 23 36 18 66 55 72 59 147 35 42 77 74
2025/2026337 162 22 70 83 0 0 0 0 0 0 0 0
Totale 2.230